Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors
Analysis of stem cell products immunological parameters and recipient outcome in autologous and allogeneic peripheral blood stem cell transplantation
Molecular profiling in patients with advanced lung or thymic cancer previously treated with immune checkpoint inhibitor therapy.
Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
Phase 1 / 2 trial of Idasanutlin in combination with Ixazomib and dexamethasone in patients with 17p deleted, relapsed multiple myeloma
Patient-Reported Outcomes, Cognitive Decline, and Costs of Autologous Stem Cell Transplant After Induction for Patients with Multiple Myeloma
PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma
Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.
